[Skip to Navigation]
Sign In
Views 394
Citations 0
Comment & Response
September 21, 2021

Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

Author Affiliations
  • 1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 2Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, New York
JAMA. 2021;326(11):1067. doi:10.1001/jama.2021.11477

To the Editor NOR-DRUM Part A1 is the first randomized clinical trial to investigate the role of proactive therapeutic drug monitoring (TDM) during initiation of infliximab therapy in adults with various immune-mediated inflammatory disorders. The primary end point of clinical remission at week 30 did not differ significantly between the proactive TDM and standard therapy groups. The subset of patients with inflammatory bowel disease (IBD) had a similar outcome for the primary study end point as well as for numerous secondary outcomes.1

Add or change institution